详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients

100| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Gynecologic Oncology Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China [2]Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, P.R. China [3]Department of Hepatobiliary and Pancreatic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China [4]Anesthesia Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China

出处：

DOI：

ISSN：

关键词： Integrins Ovarian Neoplasms Prognosis

摘要：

Background: ITGB8 encodes a beta subunit of integrin (integrin beta 8), which is upregulated in some types of cancer. In the current study, we examined the expression profile of ITGB8 in serous ovarian cancer (SOVC) and investigated its potential as an independent prognostic indicator for overall survival (OS) and recurrence-free survival (RFS) in high-grade SOVC. Material/Methods: A secondary study was conducted based on genomic and survival data in large online databases, including the Gene Expression Omnibus (GEO), the Human Protein Atlas (HPA), and the Cancer Genome Atlas-Ovarian cancer (TCGA-OV). Kaplan-Meier curves were generated to evaluate the association between ITGB8 expression and OS/RFS. Univariate and multivariate analysis were performed with the Cox regression model. Results: ITGB8 was significantly upregulated in ovarian cancer tissues compared to that in normal ovary tissues. High-grade SOVC patients with high ITGB8 expression had significantly shorter OS and RFS compared to their low-expression counterparts. Increased ITGB8 expression might be an independent prognostic indicator of unfavorable OS (HR: 1.424, 95% CI: 1.228-1.653, p<0.001) and RFS (HR: 2.167, 95% CI: 1.507-3.114, p<0.001) in high-grade SOVC. DNA amplification was frequent (149/509, 29.3%) in high-grade SOVC patients and was associated with increased ITGB8 expression compared to the copy-neutral cases. Conclusions: ITGB8 expression might be a valuable prognostic biomarker in high-grade SOVC, the expression of which might be regulated by its DNA copy numbers.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

最新[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

JCR分区：

出版当年[2018]版：

Q3 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 2.2 最新[2023版] 2.5 最新五年平均 1.98 出版当年[2018版] 1.923 出版当年五年平均 1.894 出版前一年[2017版] 1.918 出版后一年[2019版]

第一作者：

第一作者机构： [1]Gynecologic Oncology Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Prognosis of epithelial ovarian cancer related to its ascites [2]Ovarian metastasis in patient with endometrial carcinoma [3]Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China [4]PET imaging of VEGFR and integrins in glioma tumor xenografts using 89Zr labelled heterodimeric peptide. [5]Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells. [6]Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells [7]卵巢恶性生殖细胞肿瘤手术治疗方式及疗效的多中心临床研究 [8]Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells [9]替拉扎明联合磷脂酰肌醇-3激酶抑制剂对人卵巢癌细胞的抑制作用 [10]The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials(Open Access)